Author:
Qu Wang,Fu Cheng,Han Weiqing,Luo Hong,Quan Jizhong,Chen Lijun,Liao Yong,Hu Changlu,Hu Hailong,Niu Yinong,Xu Danfeng,Chen Minfeng,Chen Jimin,Liu Yongda,Chen Guojun,Luo Zhanxiong,Shi Benkang,Sun Yongkun,Zhou Fangjian,Zhou Aiping
Reference16 articles.
1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Cancer statistics in China and United States, 2022: profiles, trends, and determinants;Xia;Chin Med J (Engl),2022
3. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients;Abida;Hematol Oncol Clin North Am,2015
4. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma;van der Heijden;N Engl J Med,2023
5. EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC);Powles;Ann Oncol,2023